{"id":694535,"date":"2026-01-14T03:34:10","date_gmt":"2026-01-14T03:34:10","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/694535\/"},"modified":"2026-01-14T03:34:10","modified_gmt":"2026-01-14T03:34:10","slug":"first-leukaemia-patient-to-get-pioneering-drug-on-nhs-says-it-is-very-sci-fi","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/694535\/","title":{"rendered":"First leukaemia patient to get pioneering drug on NHS says it is &#8216;very sci-fi&#8217;"},"content":{"rendered":"<p class=\"ssrcss-1q0x1qg-Paragraph e1jhz7w10\">Oscar said he was surprised the treatment could pack such a powerful punch in such a small dose. <\/p>\n<p class=\"ssrcss-1q0x1qg-Paragraph e1jhz7w10\">&#8220;It&#8217;s very sci-fi, but if it means it gets rid of the cancer permanently and my own cells can do it it&#8217;s just fantastic.&#8221;<\/p>\n<p class=\"ssrcss-1q0x1qg-Paragraph e1jhz7w10\">Oscar had a second infusion of 300 million cells yesterday, marking the end of his CAR-T treatment.<\/p>\n<p class=\"ssrcss-1q0x1qg-Paragraph e1jhz7w10\">As this is a &#8220;living drug&#8221;, the cancer-killing T-cells stay in the body for a long time and will continue to grow and work inside the patient after the final infusion.<\/p>\n<p class=\"ssrcss-1q0x1qg-Paragraph e1jhz7w10\">The CAR-T therapy is manufactured by Autolus, a spin-out company from University College London.<\/p>\n<p class=\"ssrcss-1q0x1qg-Paragraph e1jhz7w10\">During clinical trials, the patient&#8217;s cells had to be sent to laboratories in the US.<\/p>\n<p class=\"ssrcss-1q0x1qg-Paragraph e1jhz7w10\"><a href=\"https:\/\/www.nice.org.uk\/guidance\/ta1116\/resources\/obecabtagene-autoleucel-for-treating-relapsed-or-refractory-bcell-precursor-acute-lymphoblastic-leukaemia-pdf-2973530453903557\" class=\"ssrcss-f6h2dj-InlineLink e1kn3p7n0\" target=\"_blank\" rel=\"noopener\">The list price of the treatment is \u00a3372,000 per infusion, external<\/a>, but the NHS has a confidential discount.<\/p>\n<p class=\"ssrcss-1q0x1qg-Paragraph e1jhz7w10\">It will be available to patients over the age of 26 whose B-cell ALL has not responded to treatment or has returned at several centres in England, including Cambridge, Newcastle, Sheffield, Plymouth and London. <\/p>\n<p class=\"ssrcss-1q0x1qg-Paragraph e1jhz7w10\">Patients from Wales and Northern Ireland will need to travel to England for treatment. It has not yet been approved in Scotland.<\/p>\n<p class=\"ssrcss-1q0x1qg-Paragraph e1jhz7w10\">NHS England estimates that around 50 patients a year may benefit, but Tholouli told the BBC she believed it could be more, and predicted it would eventually be used as a first-line treatment instead of stem cell transplantation.<\/p>\n<p class=\"ssrcss-1q0x1qg-Paragraph e1jhz7w10\">Prof Peter Johnson, NHS National Clinical Director for Cancer, said it was a &#8220;landmark moment&#8221; for people with aggressive blood cancer.<\/p>\n<p class=\"ssrcss-1q0x1qg-Paragraph e1jhz7w10\">He added it was &#8220;remarkable&#8221; the treatment now delivered at NHS centres had been developed from scientific research within the UK.<\/p>\n<p class=\"ssrcss-1q0x1qg-Paragraph e1jhz7w10\">&#8220;It will help more people like Oscar live longer and healthier lives.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"Oscar said he was surprised the treatment could pack such a powerful punch in such a small dose.&hellip;\n","protected":false},"author":2,"featured_media":694536,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[748,393,4884,12,1144,712,16,15,1764],"class_list":{"0":"post-694535","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-news","8":"tag-britain","9":"tag-england","10":"tag-great-britain","11":"tag-news","12":"tag-northern-ireland","13":"tag-scotland","14":"tag-uk","15":"tag-united-kingdom","16":"tag-wales"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115891356583612295","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/694535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=694535"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/694535\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/694536"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=694535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=694535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=694535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}